Clinical Trials Browser

NETWORK × Lymphoma, Mantle-Cell × Bortezomib × Clear all

NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Active not recruiting

373 enrolled 14 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT00030875 2023-08-04

Bortezomib in Treating Patients With Mantle Cell Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Mantle-Cell

NCT00377052 2023-08-04

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Mantle-Cell

NCT00376961 2017-11-06

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Completed

68 enrolled 9 charts

Lymphoma, Lymphoma, Mantle-Cell